Our Corporate Sponsors
Corporate sponsors assist the National Fragile X Foundation by supporting our current programs and new initiatives across all strategic initiatives — advocacy, education, treatment, and research.
Our Corporate Sponsors
Corporate sponsors assist the National Fragile X Foundation by supporting our current programs and new initiatives across all strategic initiatives — advocacy, education, treatment, and research.
Meet Our 2023 Sponsors
Tetra Therapeutics
Tetra Therapeutics, a Shionogi Group Company, is a clinical-stage biotechnology company focused on developing a portfolio of therapeutic products for people suffering from Fragile X syndrome, Alzheimer’s disease, traumatic brain injury, and other brain disorders. Tetra Therapeutics is headquartered in Grand Rapids, Michigan.
Zynerba Pharmaceuticals
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. Zynerba is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome, and autism spectrum disorder.
Asuragen
Asuragen, a BioTechnique brand, takes the complexity out of Fragile X by offering Fragile X diagnostic genetic testing. Testing for Fragile X syndrome is important, especially for women who are pregnant or plan to become pregnant.
Allos Pharma
Allos Pharma is a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Their work spans three decades of research in neuroscience and intellectual disabilities.
Anavex
Anavex Life Sciences Corp is working to develop novel small molecule treatments for some of the most challenging central nervous system (CNS) diseases facing society today, including Alzheimer’s, Parkinson’s, Rett syndrome, and other rare diseases.
Autifony
Autifony Therapeutics Limited (“Autifony”) is a clinical stage biotechnology company dedicated to developing new medicines to treat rare genetic CNS disorders by deploying its pioneering ion channel drug discovery platform.
Sponsor Benefits
Interested in learning more about our Corporate Sponsorship program?
If you have questions, we’d love to hear from you! You can reach out to Kristin Bogart directly, or submit your question or comment through our contact form.
Kristin Bogart,
Senior Director, Development and Communications
kristin@fragilex.org
202-747-6209